Conferences - Visterra

Sibeprenlimab for Patients With IgA Nephropathy: Results From a Prespecified Interim Analysis of the Phase 3 VISIONARY Study

June 6, 2025 | 62nd ERA Congress

Vlado Perkovic, et al.

Sibeprenlimab for Patients With IgA Nephropathy: Results From a Prespecified Interim Analysis of the Phase 3 VISIONARY Study

Vlado Perkovic, Jonathan Barratt, Richard Lafayette, Adrian Liew, Yusuke Suzuki, Kevin Carroll, Chee Kay Cheung, Vladimir Tesař, Hernán Trimarchi, Muh Geot Wong, Hong Zhang, Dana V Rizk

>SEE PRESENTATION

Differential Impacts of APRIL and APRIL/BAFF Inhibition on Immune Populations: Implications for IgA Nephropathy Treatment and Protective Immunity

June 5, 2025 | 62nd ERA Congress

Kirk Rowley, et al.

Differential Impacts of APRIL and APRIL/BAFF Inhibition on Immune Populations: Implications for IgA Nephropathy Treatment and Protective Immunity

Kirk Rowley, Vinay Singh, Anna Roberts, Katie Heang, Prashanna Venkatasubramanian, Jacob Konaklonda, Daved Fared, Michelle Lu, Brett Hurst, Wayne W Hancock, Gregory J Babcock, Luke Robinson

>SEE POSTER

Sibeprenlimab in patients with IgA nephropathy: a Phase 2 trial

November 2, 2023 | American Society of Nephrology (ASN) Kidney Week

Jonathan Barratt, et.al.

Sibeprenlimab in patients with IgA nephropathy: a Phase 2 trial

Jonathan Barratt, Mohit Mathur, Bobby Chacko, Tak Mao Chan, Laura Kooienga, Kook-Hwan Oh, Manisha Sahay, Yusuke Suzuki, Muh Geot Wong, Jill Yarbrough, Jing Xia, Brian J G Pereira

>SEE POSTER

COVID Vaccine Responses During Sibeprenlimab Treatment of IgA Nephropathy (IgAN): A Preliminary Analysis

June 15, 2023 | 60th ERA Congress

McCafferty, et. al.

COVID Vaccine Responses During Sibeprenlimab Treatment of IgA Nephropathy (IgAN): A Preliminary Analysis

Kieran McCafferty, Marcella Pasetti, Asher Schachter, Mohit Mathur, Diane Ma, Jill Yarbrough, Mallory Shriver, Kristin Follman, Frank Engler, Yusuke Suzuki, David Oldach

Strategies For Development Of Interleukin-2 Therapy In Transplant Recipients: What Works And What Doesn’t

June 3, 2023 | American Transplant Congress

Wang, et. al.

Strategies For Development Of Interleukin-2 Therapy In Transplant Recipients: What Works And What Doesn’t

Liqing Wang, Gregory J Babcock, Wayne W Hancock

>SEE POSTER

A Novel IL-2 Mutein Induces Regulatory T Cell-Rich Microenvironment and Leads to Alloantigen-Specific Graft Acceptance

June 3, 2023 | American Transplant Congress

Ganchiku, et. al.

A Novel IL-2 Mutein Induces Regulatory T Cell-Rich Microenvironment and Leads to Alloantigen-Specific Graft Acceptance

Yoshikazu Ganchiku, Thiago J Borges, Rodrigo B Gassen, Orhan Efe, Zach Shriver, Gregory J Babcock, Leonardo V Riella

>SEE POSTER

Selective Regulatory T-Cell Expansion by A Novel IL-2 Mutein in Murine Transplant and Humanized NSG Models

June 3, 2023 | American Transplant Congress 2023

Efe, et. al.

Selective Regulatory T-Cell Expansion by A Novel IL-2 Mutein in Murine Transplant and Humanized NSG Models

Orhan Efe, Thiago J Borges, Rodrigo B Gassen, Leela Morena, Yoshikazu Ganchiku, Ayman Al Jurdi, Isadora T Lape, Zach Shriver, Gregory J Babcock, Joren C Madsen, Leonardo V Riella

A Phase 3, Multicenter, Randomized, Double-blind, Placebo-controlled Trial to Evaluate the Efficacy and Safety of Sibeprenlimab Administered Subcutaneously in Patients with Immunoglobulin A Nephropathy (IgAN)

November 5, 2022 | American Society of Nephrology (ASN) Kidney Week

Rizk, et. al.

A Phase 3, Multicenter, Randomized, Double-blind, Placebo-controlled Trial to Evaluate the Efficacy and Safety of Sibeprenlimab Administered Subcutaneously in Patients with Immunoglobulin A Nephropathy (IgAN)

Dana V Rizk, Vlado Perkovic, Richard Lafayette, Hernan Trimarchi, Jonathan Barratt, Kevin Caroll, Vladimir Tesar, Hong Zhang, Yusuke Suzuki, Adrian Liew, Muh Geot Wong, Bruce Leslie, Mohit Mathur, Jeffrey Hafkin

>SEE POSTER

Interim Analysis (IA) of a Global Phase 2 Randomized Controlled Trial of Sibeprenlimab (VIS649), an APRIL-Neutralizing Monoclonal Antibody, in IgA Nephropathy

November 3, 2022 | American Society of Nephrology (ASN) Kidney Week

Kooienga, et. al.

Interim Analysis (IA) of a Global Phase 2 Randomized Controlled Trial of Sibeprenlimab (VIS649), an APRIL-Neutralizing Monoclonal Antibody, in IgA Nephropathy

Laura Kooienga, Yusuke Suzuki, Bobby Chacko, Muh Geot Wong, Jonathan Barratt, Chris Oh, Manisha Sahay, Mohit Mathur, Xiaofeng Wang, Jill Yarbrough, Brian J G Pereira

>SEE POSTER

Role of APRIL in IgAN Pathophysiology

October 4, 2022 | Rare & Genetic Kidney Disease Drug Development Conference

Role of APRIL in IgAN Pathophysiology

Mohit Mathur